|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cancer immunotherapy comes of age显示文摘 | Topalian S Weiner G Pardoll D | 2011 | J Clin Oncol2011，29，36： | 1 |
| 2 | Safety, activity, and immune correlates of anti-PD-1 antibody in eancer显示文摘 | Topalian S L HodiF S Brahmer J R | 2012 | N Engl J Med2012，366，26： | 1 |
| 3 | Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity显示文摘 | Topalian S L Drake C G Pardoll D M | 2012 | Curr Opin Immunol2012，24，2： | 1 |
| 4 | Cancer immunotherapy comes of age显示文摘 | Topalian S L Weiner G J Pardoll D M | 2011 | J Clin Oncol2011，29，： | 1 |
| 5 | Safety, activity, andimmune correlates of anti-PD-1 antibody in cancer 显示文摘 | Topalian S L Hodi F S Brahmer J R | 2012 | N EngI J Med2012，366，26： | 1 |
| 6 | Safety, ac- tivity, and immune correlates of anti - PD - 1 antibody in cancer 显示文摘 | TOPALIAN S L HODI F S BRAHMER J R | 2012 | N Engl J Med2012，366，26： | 1 |
| 7 | Targeting the PD-1/B7- HI(PD-El) pathway to activate anti-tumor immunity显示文摘 | Topalian S L Drake C G Pardoll D M | 2012 | Current Opinion in Immunology2012，24，2： | 1 |
| 8 | Survival, durable tumor remission, and long - term safety in patients with advanced melanoma receiving nivolumab 显示文摘 | TOPALIAN S L SZNOL M MCDERMOTY D F | 2014 | J Clin Oncol2014，32，10： | 1 |
| 9 | Safety,activity,and immune correlates of anti-PD-1 antibody in cancer 显示文摘 | TOPALIAN S L HODI F S BRAHMER J R | 2012 | N Engl J Med2012，366，26： | 1 |
| 10 | Survival,durable tumor remission,and long-term safety in patients with advanced melanoma receiving nivolumab 显示文摘 | TOPALIAN S L SZNOL M MCDERMOTT D F | 2014 | J Clin Oncol2014，32，10： | 1 |
| 11 | Randoomized comparison of high-dose and low-dose intravenous interleukin-2for the therapy of metastatic renal cell carcinoma:an internal re- port显示文摘 | YANG JC TOPALIAN SL PARKINSON S | 1994 | J Clin Oneol1994，12，： | 1 |
| 12 | Cancer immunotherapy comes of age 显示文摘 | Topalian S L Weiner G J Pardoll D M | 2011 | J Clin Oncol2011，29，： | 1 |
| 13 | Safety,activity,and immune correlates of anti-PD-1 antibody in cancer显示文摘 | TOPALIAN S L HODI F S BRAHMER J R | 2012 | N Engl J Med2012，366，26： | 1 |
| 14 | Targeting the PD-1/BT- H1 (PD-L1) pathway to activate anti-tumor immunity显示文摘 | Topalian S L Drake C G Pardoll D M | 2012 | Curr Opin immunol2012，24，2： | 1 |
| 15 | Safety,activity,and im- mune correlates of anti PD-1 antibody in caneer显示文摘 | Topalian S L Hodi F S Brahmer J R | 2012 | N Engl J Med2012，366，26： | 1 |
| 16 | MHC class Ⅱ restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy显示文摘 | Topalian S L | 1994 | Curr Opin Immunol1994，6，5： | 1 |
| 17 | Iatrogenic pulmonary ar- tery rupture during Swan - Ganz catheter placement - - a novel therapeutic approach 显示文摘 | KALRA A HEITNER S TOPALIAN S | 2013 | Catheter Cardiovasc Interv2013，81，1： | 1 |
| 18 | Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report显示文摘 | Yang J C Topalian S L Parkinson D | 1994 | J Clin Oncol1994，12，8： | 1 |
| 19 | Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor显示文摘 | Skornick Y Topalian S Rosenberg SA | 1990 | J Biol Response Mod1990，9，4： | 1 |
| 20 | Immunization of HLA-A * 0201 and/or HLA-DPbetal* 04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen显示文摘 | Khong H T Yang J C Topalian S L | 2004 | J Immunother2004，27，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员